Evidence map›Paper›PMID 40760006›Full record

Trial reportScientific reports2025

Long term efficacy and safety of MICT of cardiopulmonary function in patients after TAVR extended follow up of ENERGY study.

Yu-Shan Li, Qiang Ren, Xing-Bo Mu, Kai Xu, Yan-Chun Liang, Jian Zhang, Geng Wang, Yan-Xia Wang, Cai-Lian Wang, Yi Zhang and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yu-Shan Li *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Qiang Ren *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Xing-Bo MuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Kai XuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Yan-Chun LiangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Jian ZhangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Geng WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Yan-Xia WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Cai-Lian WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Yi ZhangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Sheng-Yi WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
Quan-Yu ZhangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. zqyfmmu@foxmail.com.
Ya-Ling HanState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China. hanyaling@163.net.

Funding

Department of Science and Technology of Liaoning Province 2022JH2/101500028National Natural Science Foundation of China 32071116
6 · The paper itself

Abstract

The ENERGY study demonstrated that 3-month moderate-intensity continuous training (MICT) improved the cardiopulmonary function and exercise capacity for patients after transcatheter aortic valve replacement (TAVR). However, the long-term effects remained uncertain. Therefore, the present study evaluated the long-term efficacy and safety of MICT in patients undergoing TAVR. 64 patients were randomized into MICT (3 times per week) or control groups (one-time physical activity advice). Outcomes were assessed using the 12-month changes in cardiopulmonary exercise testing (CPET) parameters, 6-minute walk test (6MWT), SF-12 quality of life score, New York Heart Association (NYHA) class, echocardiographic and laboratory parameters. After 12 months, the MICT group showed significantly greater improvements in peak VO

Indexed as

Aortic Valve StenosisExercise TherapyTranscatheter Aortic Valve ReplacementAgedAged, 80 and overExercise TestExercise ToleranceFemaleFollow-Up StudiesHumansMaleQuality of LifeTreatment OutcomeWalk TestCardiac rehabilitation (CR)Cardiopulmonary exercise testing (CPET)Moderate-Intensity continuous training (MICT)Quality of life (QoL)Transcatheter aortic valve replacement (TAVR)

Identifiers

PMID40760006
PMCPMC12322168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.